Morphosys AG O.N. (MORG)

20.560
-1.090(-5.03%)
  • Volume:
    248,097
  • Bid/Ask:
    20.440/20.880
  • Day's Range:
    20.360 - 22.080

MORG Overview

Prev. Close
20.56
Day's Range
20.36-22.08
Revenue
173.88M
Open
21.85
52 wk Range
16.075-43.29
EPS
-24.97
Volume
248,097
Market Cap
702.19M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
197,705
P/E Ratio
-0.897
Beta
0.922
1-Year Change
-49.85%
Shares Outstanding
34,153,376
Next Earnings Date
Nov 16, 2022
What is your sentiment on Morphosys AG?
or
Market is currently closed. Voting is open during market hours.

Morphosys AG O.N. News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Morphosys AG Earnings Miss, Revenue Beats In Q2
    • ByInvesting.com-

    Investing.com - Morphosys AG reported on Wednesday second quarter earnings that missed analysts' forecasts and revenue that topped expectations. Morphosys AG announced earnings...

  • Germany stocks mixed at close of trade; DAX up 0.57%
    • ByInvesting.com-

    Investing.com – Germany stocks were mixed after the close on Tuesday, as gains in the Industrials, Food & Beverages and Financial Services sectors led shares higher while losses in...

Morphosys AG O.N. Analysis

  • MorphoSys Continues To Progress

    At the American Society of Hematology (ASH) annual meeting, compelling early combination data on MOR208 and MOR202 were presented. MOR208 with lenalidomide in previously untreated...

  • MorphoSys: Getting Aggressive On Pipeline

    Getting aggressive on its pipelineMorphoSys (L:0NDV) recently communicated its plans for its proprietary pipeline, which will help transform the company into a fully integrated...

Morphosys AG O.N. Company Profile

Morphosys AG O.N. Company Profile

Employees
771
Market
Germany
  • Type:Equity
  • Market:Germany
  • ISIN:DE0006632003
  • WKN:663200

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer’s diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Read More

Analyst Price Target

Average37.056 (+80.23% Upside)
High65
Low24
Price20.56
No. of Analysts10
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellSellBuySell
Technical IndicatorsStrong SellStrong SellStrong SellStrong BuyStrong Sell
SummaryStrong SellStrong SellStrong SellStrong BuyStrong Sell
  • Why its going down
    0
    • from now it will move up above 50 ...
      1
      • Obviously you were wrong.
        0
      • in Aug moved up over 50 and i sold all shares at 49.88... now i dont care
        0
    • I wounder why the stock has been hit so hard? Its almost @50% ot march last year when the entire market crashed!! I dont beleive lowering the upper limit of the FY revenue guidance is the driver. I have to say that ive not spent quality time understanding the fundamental of this company, i only strated to follow it recently. Appreciate your insights. Thanks
      0
      • Any idea?
        0
        • Announced a narrowing of revenue guidance. There are better options out there, but today might be a good entry point as the negative reaction (incl. yesterday) seems excessive.
          0
      • https://ch.marketscreener.com/kurs/aktie/MORPHOSYS-AG-436425/news/COMPANY-TALK-J-J-nbsp-41-Prozent-Plus-mit-Morphosys-Wirkstoff-33013409/
        0
        • strong buy
          0
          • European approval for tafasitamab is due at the end of May
            0
            • Damn good results published!!!
              0
              • When (what time)  is the news public concerning their yearresults?
                0
                • buy buy buy
                  0